ERBB2 and breast carcinoma: Based on previous studies and clinical practice, we conducted a retrospective review of premenopausal patients with HR+/HER2+ early‐stage breast cancer treated with trastuzumab to investigate the population that may benefit from the addition of OFS and the prognostic value of clinicopathological factors.